Fc 11a-2 

Fc 11a-2, a benzimidazole compound, is an orally active and potent NLRP3 inflammasome inhibitor. Fc 11a-2 restrains the formation of NLRP3 inflammasome by inhibiting activation of caspase-1 and thus the activation of IL-1b/IL-18. Fc 11a-2 prevents the development of Dextran sulfate sodium (DSS; HY-116282C)-induced murine experimental colitis^[1][2][3].

Fc 11a-2 (10 μM) suppresses the release of IL-1β and IL-18 from LPS (HY-D1056)-primed THP-1 cells activated with ATP exhibiting an IC₅₀ of about 10 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Fc 11a-2 (3-30 mg/kg; Orally; from day 1 to day 10) dose-dependently attenuates the loss of body weight and shortening of colon length induced by DSS^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

236.31

C₁₆H₁₆N₂

960119-75-9

CC1=CC=C2N(CC)C(C3=CC=CC=C3)=NC2=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Liangkun Pan, et al. Synthesis and Biological Evaluation of Novel Benzimidazole Derivatives and Analogs Targeting the NLRP3 Inflammasome. Molecules. 2017 Jan 30;22(2):213.  [Content Brief]

  [2]. Wen Liu, et al. A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem Pharmacol. 2013 May 15;85(10):1504-12.  [Content Brief]

  [3]. Biswadeep Das, et al. Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models. Molecules. 2021 Aug 18;26(16):4996.  [Content Brief]